Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of (177)Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells

SIMPLE SUMMARY: The peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTA-octreotate (LuTate) is recommended for neuroendocrine tumors (NETs) which overexpress somatostatin receptors (SSTR). A combination of LuTate with chemotherapy improves its objective response in NET patients, and here...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Rashmi G., Merlin, Marine A., Adant, Samuel, Zine-Eddine, Fayçal, Beauregard, Jean-Mathieu, Shah, Girish M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828052/
https://www.ncbi.nlm.nih.gov/pubmed/33435224
http://dx.doi.org/10.3390/cancers13020232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828052/
https://www.ncbi.nlm.nih.gov/pubmed/33435224
http://dx.doi.org/10.3390/cancers13020232

Ejemplares similares